Dedication to science and research is the founding principle and passion that makes Therome who we are. Take a look at why Therome is an innovator in ophthalmology.

OUR
SCIENCE
PRE-CLINICAL STAGES
Pre-clinical trials for this liposomal drug delivery system have shown promising results. More information and study results can be provided upon signing of an NDA.

ANIMAL STUDIES FOR
OCULAR PHARMACOKINETICS
In vivo studies were performed using Dutch Belted Rabbits, and the ocular distribution of the model fluorescent tagged antibody Bevacizumab (Avastin) was examined at regular intervals by non-invasive imaging using a Fluorotron. When a single standard dose of 2.5 mg/ml of Bevacizumab was injected into the rabbit’s eye, the drug levels in the vitreous dropped to zero in 6 weeks. On the other hand, when the drug was encapsulated in the liposomes, the minimum therapeutic concentration in the vitreous was maintained up to 22 weeks. The concentrations and anti-VEGF binding affinity of the released antibodies were confirmed using ELISA on samples obtained from the rabbit’s eye at regular intervals.
Want to learn more about our patented delivery system?